SCHEMBL3205151

SCHEMBL3205151

[CH2]Cc1cc(O)c(O)c(O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SELP P16109 3/20 0.41
SELL P14151 2/20 0.41
SELE P16581 2/20 0.41
HSD17B10 Q99714 3/20 0.37
ALOX15 P16050 3/20 0.37
CYP2C9 P11712 1/20 0.37
KDM4E B2RXH2 4/20 0.36
MAPT P10636 4/20 0.36
TDP1 Q9NUW8 4/20 0.36
ALDH1A1 P00352 3/20 0.36
LMNA P02545 3/20 0.36
MAPK1 P28482 3/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA4 P22748 2/20 0.36
CA6 P23280 2/20 0.36
TP53 P04637 2/20 0.36
SNCA P37840 2/20 0.36
CA12 O43570 1/20 0.36
CA3 P07451 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11408792 0.75 CA1 (0.52) SELPSELLSELEHSD17B10ALOX15
SCHEMBL3931834 0.73 ACHE (0.55) HSD17B10ALDH1A1LMNACA1CA2
SCHEMBL68262 0.73 ACHE (0.55) SELPSELLSELEHSD17B10ALOX15
SCHEMBL10551451 0.72 CA1 (0.50) CYP2C9KDM4EMAPTALDH1A1LMNA
SCHEMBL490700 0.72 CA1 (0.64) HSD17B10ALOX15CYP2C9KDM4EMAPT
SCHEMBL6103705 0.72 TTR (0.50) HSD17B10ALOX15CYP2C9MAPTALDH1A1
SCHEMBL9171319 0.71 IGF1R (0.45) ALOX15MAPK1HPGDHTTIGF1R
SCHEMBL633156 0.71 RECQL (0.46) SELPSELLSELEHSD17B10ALOX15
SCHEMBL14234185 0.71 SELL (0.41) SELPSELLSELEHSD17B10ALOX15
SCHEMBL1173818 0.71 TRPA1 (0.56) SELPSELLSELEHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937090-B2 Parakeratosis inhibitor, pore-shrinking agent and external composition for skin SHISEIDO COMPANY, LTD. (JP) 2015-01-20 US disclosed
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin SHISEIDO COMPANY, LTD. (JP) 2012-09-13 US disclosed
US-20120165409-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2012-06-28 US disclosed
US-20100035881-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2010-02-11 US disclosed
EP-1941861-A1 WRINKLE-IMPROVING AGENT Shiseido Company, Limited (JP) 2008-07-09 EP disclosed
EP-1880711-A1 PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN Shiseido Company, Limited (JP) 2008-01-23 EP disclosed
EP-0719258-B1 CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS OTSUKA PHARMA CO LTD (JP) 2001-10-31 EP disclosed
US-5786367-A OXYGEN SCAVENGERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1998-07-28 US disclosed
EP-0719258-A1 CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1996-07-03 EP disclosed
WO-1996002508-A1 CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1996-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035881-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 SELP 4488/4885SELL 4602/4885SELE 4654/4885
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin CUTA, AAAS, NUP160 SELP 3546/4885SELL 4725/4885SELE 4076/4885
US-20120165409-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 SELP 4501/4885SELL 4709/4885SELE 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.